NOTA Labs

Executive Summary

NOTA Labs is a private biotechnology company headquartered in San Francisco, founded in 2021, that specializes in developing novel nitric oxide (NO) delivery systems. Nitric oxide is a naturally occurring molecule with potent antiviral, antimicrobial, anti-thrombotic, anti-inflammatory, and vasodilatory properties, and it also plays a crucial role as a signaling molecule in the brain. The company's platform aims to augment the body's own NO production to treat and prevent a wide range of life-threatening illnesses, including infectious diseases, cardiovascular conditions, and inflammatory disorders. By engineering innovative delivery mechanisms, NOTA seeks to overcome the challenges of NO's short half-life and systemic toxicity, enabling targeted and sustained therapeutic effects. The technology has broad applicability across multiple indications, positioning the company to address significant unmet medical needs. Currently operating at an early stage, NOTA Labs has achieved "Approved" status, likely indicating regulatory or institutional approval for initial development activities. The company has not disclosed total funding or valuation, but its focus on a versatile endogenous molecule and its potential to impact diverse disease areas make it an attractive candidate for strategic partnerships and investment. However, as a preclinical-stage firm, risks include scientific validation, manufacturing scalability, and clinical trial outcomes. The management's ability to advance lead candidates into the clinic and secure non-dilutive funding will be critical. Overall, NOTA Labs represents a promising platform with substantial upside, albeit with typical early-stage biotech uncertainties.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase I Clinical Trial for Lead NO Delivery Candidate60% success
• Q4 2026Strategic Partnership with Major Pharmaceutical Company40% success
• Q2 2026Series A Funding Round70% success